Association between diabetes and heart failure after coronary artery bypass grafting: Danish register-based cohort

Benedicte Bay Oxholm Brodersen1, Line Tribler Kristiansen1, Sidsel le Fevre Karlsen1

  • 1The Faculty of Medicine, Aalborg University, Aalborg, Denmark.

Insights

Patients with diabetes mellitus (DM) face a significantly higher risk of heart failure (HF) after coronary artery bypass grafting (CABG). This increased risk persists for up to ten years post-surgery, highlighting a critical concern for this patient group.

Area of Science:

  • Cardiovascular Medicine
  • Diabetology
  • Surgical Outcomes Research

Background:

  • Ischemic heart disease (IHD) is a leading global cause of mortality.
  • Diabetes mellitus (DM) affects approximately 25% of patients undergoing coronary artery bypass grafting (CABG).
  • DM patients exhibit a heightened risk of mortality from heart failure (HF) post-revascularization.

Purpose of the Study:

  • To compare the risk of developing heart failure (HF) after coronary artery bypass grafting (CABG) in patients with and without diabetes mellitus (DM).

Main Methods:

  • A large, nationwide, register-based cohort study included patients who underwent CABG between 2000 and 2020.
  • Cox regression and g-formula methods were employed to analyze the association between DM status and HF outcomes.
  • Absolute risk (AR) and risk difference (RD) were calculated for HF and mortality.

Main Results:

  • The study included 34,855 patients, with 19.8% having DM.
  • The 10-year absolute risk of HF after CABG was 35.1% for DM patients versus 26.4% for non-DM patients (p < 0.001).
  • The risk difference for HF was notably higher in DM patients, increasing from 3.7 percentage points (pp.) at year 1 to 8.6 pp. at year 10.

Conclusions:

  • Patients with diabetes mellitus (DM) experience a significantly elevated risk of heart failure (HF) following coronary artery bypass grafting (CABG).
  • This increased HF risk in DM patients persists for up to ten years post-CABG.
  • The findings underscore the importance of managing DM in patients undergoing CABG to mitigate long-term HF risk.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
308
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K